Pathological Hallmarks of Alzheimer's Disease Antibody Sampler Kit #74113
Product Information
Kit Usage Information
Protocols
- 7074: Western Blotting
- 8243: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence
- 12885: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence
- 12990: Western Blotting, Immunofluorescence
- 14974: Western Blotting, Immunofluorescence
- 14975: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence
- 20194: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, Immunofluorescence
- 32098: Western Blotting, Immunofluorescence
- 46687: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence, Immunofluorescence
- 49561: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence
Product Description
Specificity / Sensitivity
Pathological Hallmarks of Alzheimer's Disease Antibody Sampler Kit includes Tau (D1M9X) XP® Rabbit mAb that recognizes total tau, and antibodies that recognize various phosphorylated tau epitopes found in Alzheimer's disease, including Phospho-Tau (Thr205) (E7D3E), Phospho-Tau (Ser404) (D2Z4G), and Phospho-Tau (Thr181) (D9F4G). Additionally, this kit includes antibodies that detect various β-Amyloid peptides of the APP human protein, including β-Amyloid (D54D2) XP® Rabbit mAb, which also detects transgenically expressed human APP in mouse. β-Amyloid (pE3 Peptide) (D5N5H) Rabbit mAb recognizes recombinant pE3 peptides but does not cross-react with the non-E3 peptides. β-Amyloid (1-40 Specific) (D8Q7I) Rabbit mAb does not cross-react with other β-amyloid peptides. β-Amyloid (1-43 Preferred) (E8C2D) Rabbit mAb and β-Amyloid (1-42 preferred) (D9A3A) Rabbit mAb both detect transgenically expressed human APP in mouse models.
Source / Purification
Tau antibodies include peptides corresponding to residues surrounding Asp430, phosphorylated at Thr205, Ser400/Thr403/Ser404, and Thr181 of human tau. Monoclonal antibodies are produced by immunizing rabbits with synthetic Aβ peptides corresponding to residues near the carboxy terminus of human β-amyloid (1-42), (1-40), (1-43), (pE3) peptide, and several peptides of Aβ, such as Aβ-37, Aβ-38, Aβ-39, Aβ-40, and Aβ-42.
Background
Tau is a heterogeneous microtubule-associated protein that promotes and stabilizes microtubule assembly, especially in axons. Six isoforms with different amino-terminal inserts and different numbers of tandem repeats near the carboxy terminus have been identified, and tau is hyperphosphorylated at approximately 25 sites by ERK, GSK-3, and CDK5 (1,2). Phosphorylation decreases the ability of tau to bind to microtubules. Neurofibrillary tangles are a major hallmark of Alzheimer's disease; these tangles are bundles of paired helical filaments composed of hyperphosphorylated tau. In particular, phosphorylation at Ser396 by GSK-3 or CDK5 destabilizes microtubules. Furthermore, research studies have shown that inclusions of tau are found in a number of other neurodegenerative diseases, collectively known as tauopathies (1,3). The cerebrospinal fluid concentration of tau phosphorylated at Thr181 has been proposed to be a biomarker for the study of neurodegenerative disorders (4).
Amyloid β (Aβ) precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that exists as several isoforms (4). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (4). The extracellular deposition and accumulation of the released Aβ fragments form the main components of amyloid plaques in Alzheimer's disease (4). APP can be phosphorylated at several sites, which may affect the proteolytic processing and secretion of this protein (5-8). Aβ-43 has been suggested as a biomarker in early onset of Alzheimer's disease, where patients have lower levels of Aβ-43 in cerebrospinal fluid (8-10). Several studies have shown that Aβ toxicity of Aβ-43 is as high as Aβ-42 or Aβ-40 in different models of Alzheimer's disease, including mouse models and human disease (10).
- Johnson, G.V. and Stoothoff, W.H. (2004) J Cell Sci 117, 5721-9.
- Hanger, D.P. et al. (1998) J Neurochem 71, 2465-76.
- Bramblett, G.T. et al. (1993) Neuron 10, 1089-99.
- Mitchell, A.J. (2009) J Neurol Neurosurg Psychiatry 80, 966-75.
- Selkoe, D.J. (1996) J Biol Chem 271, 18295-8.
- Caporaso, G.L. et al. (1992) Proc Natl Acad Sci U S A 89, 3055-9.
- Hung, A.Y. and Selkoe, D.J. (1994) EMBO J 13, 534-42.
- Suzuki, T. et al. (1994) EMBO J 13, 1114-22.
- Ando, K. et al. (1999) J Neurosci 19, 4421-7.
- Iijima, K. et al. (2000) J Neurochem 75, 1085-91.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.